Mural Oncology plc (MURA) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 1.1M | 0 | 0 | 0 | 900K | 0 | 0 | 779K | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | -1.1M | 0 | 0 | 0 | -900K | 0 | 0 | -779K | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -22.22% | - | - | 100% | - | - | - | - | - | - |
| Operating Expenses | 3.97M | 30.26M | 34.38M | 35.85M | 34.1M | 33.38M | 34.03M | 58.51M | 43.93M | 47.26M | 57.59M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 8.25M | 8.08M | 6.96M | 7.18M | 6.51M | 6.73M | 7.17M | 16.27M | 5.96M | 4.73M | 12.31M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 4.29M | 23.28M | 27.43M | 28.67M | 27.59M | 27.14M | 26.87M | 42.24M | 40.35M | 42.53M | 45.27M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -1000K | -1000K | 0 | 0 | 0 | -500K | 0 | 0 | -1000K | 0 | 0 |
| Operating Income | -3.97M | -31.36M | -34.38M | -35.85M | -34.1M | -34.28M | -34.03M | -58.51M | -44.71M | -47.26M | -57.59M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 88.37% | 8.52% | -1.03% | 38.72% | 23.74% | 27.47% | - | -1.61% | - | - | - |
| EBITDA | -3.17M | -30.26M | -33.53M | -34.99M | -33.2M | -33.38M | -33.19M | -57.9M | -43.93M | -46.61M | -57.09M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 90.45% | 9.35% | -1.04% | 39.57% | 24.43% | 28.39% | - | -1.42% | - | - | - |
| D&A (Non-Cash Add-back) | 797K | 1.1M | 851K | 868K | 899K | 900K | 846K | 613K | 779K | 645K | 497K |
| EBIT | -3.71M | -47.98M | -34.38M | -35.85M | -34.1M | -31.56M | -34.03M | -58.51M | -46.31M | -47.26M | -57.59M |
| Net Interest Income | 0 | 0 | 1.25M | 1.58M | 2.34M | 2.71M | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 1.25M | 1.58M | 2.34M | 2.71M | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 260K | -16.63M | 1.25M | 1.58M | 2.34M | 2.71M | 3.12M | 951K | -1.6M | 0 | 0 |
| Pretax Income | -3.71M | -47.98M | -33.14M | -34.27M | -31.76M | -31.56M | -30.92M | -57.56M | -46.31M | -47.26M | -57.59M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.98M | 4.97M | 2.91M | 1.22M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -3.43% | -10.72% | -6.15% | -2.12% |
| Net Income | -3.71M | -47.98M | -33.14M | -34.27M | -31.76M | -31.56M | -30.92M | -59.54M | -51.28M | -50.16M | -58.8M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 88.33% | -52.02% | -7.18% | 42.43% | 38.07% | 37.08% | - | -1.24% | - | - | - |
| Net Income (Continuing) | -3.71M | -47.98M | -33.14M | -34.27M | -31.76M | -31.56M | -30.92M | -59.54M | -51.28M | -50.16M | -58.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.21 | -2.78 | -1.93 | -2.01 | -1.87 | -1.86 | -1.84 | -3.57 | -3.07 | -3.13 | -3.52 |
| EPS Growth % | 88.77% | -49.46% | -4.89% | 43.7% | 39.09% | 40.58% | - | -1.42% | - | - | - |
| EPS (Basic) | -0.21 | -2.78 | -1.93 | -2.01 | -1.87 | -1.86 | -1.84 | -3.57 | -3.07 | -3.13 | -3.52 |
| Diluted Shares Outstanding | 17.32M | 17.27M | 17.17M | 17.07M | 17.03M | 16.92M | 16.79M | 16.69M | 16.69M | 16.69M | 16.69M |
| Basic Shares Outstanding | 17.32M | 17.27M | 17.17M | 17.07M | 17.03M | 16.92M | 16.79M | 16.69M | 16.69M | 16.69M | 16.69M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |